What will the whole plan cost?

Ask for the total, not the headline

For the same medicine, the maker’s published price can differ from a cash price or an insurance copay. A copay is your part of the bill when insurance covers the medicine.

• Maker cash offers for branded diabetes and weight medicines were mostly about $149 to $499 for a month, as of September 26, 2026.
• Some offers require the next supply to be ordered within a set time. Missing that deadline can raise the price. Ask for the refill deadline for your offer.
• The product decides what a “month” includes: a bottle, a box, or a supply for 28 days. Ask how much medicine comes with the price and how many days it covers.
• That range is for medicine. It is not a quote for the whole course of care.

Put each charge on the same page

On September 26, 2026, advertised prices were checked for six national services offering online weight care. Five charged a monthly membership, with medicine costing extra. This was a small set of offers, not a survey of every plan; ask what your own offer includes.

• Ask for the visit or membership fee, medicine charge, any tests, shipping, and follow-up costs in writing.
• Ask whether the advertised amount is an introductory rate or requires payment ahead of time.
• Ask how the fee is handled when no prescription is written, and how cancellation works.
• Ask how often you will be billed for each item. Compare the total for the same number of months, including later bills as well as the first payment.

Insurance cover depends on the plan and the use

Prior authorization means getting the plan’s approval for payment in advance. A formulary is its list of covered medicines.

• On September 26, 2026, Medicare’s ordinary drug benefit (Part D) continued to exclude medicines used solely for weight loss.
• For another accepted condition, such as diabetes, Medicare may cover that same medicine. Your plan’s medicine list and rules for approving payment still determine cover.
• Give your plan the exact product name and the condition being treated, then ask about cover. Ask about tests and visit fees separately.

Medicare has a separate temporary program

GLP-1 medicines act like a signal made by the body; that signal affects blood sugar and appetite. Medicare’s temporary program for certain weight medicines in this group is called the Medicare GLP-1 Bridge. It handles approval and payment separately from your usual Part D drug cover.

• As of September 26, 2026, eligible people using this program pay a $50 copay for each monthly supply.
• The program begins July 1, 2026; its final day is December 31, 2027.
• The program needs a prescription and approval in advance, with ongoing food and physical-activity changes as part of treatment. The health and plan rules below decide who can use it.
• Part D’s yearly cap on medicine costs you pay does not include this $50 payment. Your other Part D medicine bills still follow the usual plan rules. Coupons cannot reduce the program’s payment.

Who can use the temporary program?

The eligibility rules below were checked on September 26, 2026. The prescriber checks your health measures when GLP-1 treatment began. Body mass index (BMI) uses height and weight to give a number; ask the prescriber to check it in your record.

• You must be 18 or older, with either BMI of 35 or more or one of the lower-BMI health tests below.
• For BMI of 30 or more, qualifying problems include heart failure of the “preserved ejection fraction” type; kidney disease at stage 3a or a later stage; or blood pressure above 140 (top reading) or 90 (bottom reading) despite two blood pressure medicines.
• For a BMI of 27 or more, qualifying health problems include a previous heart attack or stroke, pre-diabetes, or disease in arteries outside the heart that causes symptoms (peripheral artery disease).
• A type 2 diabetes diagnosis rules out this temporary program. That use goes through the usual Part D drug cover instead.
• Moderate to severe obstructive sleep apnea (blocked breathing during sleep) also rules it out, as does noncirrhotic MASH with moderate to advanced liver scarring. MASH is a fatty-liver illness; “noncirrhotic” means it has not reached the scarring stage called cirrhosis. Not every fatty-liver diagnosis rules it out. Ask the prescriber to check the exact diagnosis in your record.
• A prescription to reduce the risk of a major heart or blood-vessel event goes through Part D instead. If a GLP-1 medicine was already paid for through Part D on your behalf in 2026, the temporary program is unavailable to you in 2026.
• Your plan must also be a Medicare Advantage coordinated care plan with drug cover or a stand-alone Part D drug plan. Ask the plan to confirm its type and the prescriber to check every eligibility rule before treating $50 as your price.